linjc16/ctgov huggingface dataset:
Looking Beyond the Immediate Effects of Lumbar Spinal Manipulation Using Pain Pressure Threshold in Asymptomatic Individuals

Study Overview
=================
Brief Summary
-----------------
The goal of this clinical trial is to test in the effects of pain pressure threshold (PPT) looking out to 30 minutes in the lumbar spine. The main question[s] it aims to answer are: • Is there a difference between PPT from baseline, immediately after, or 30 minutes after compared to sham ultrasound control group? Participants will be exposed to sham ultrasound or sidelying lumbar manipulation with between groups and within group comparisons of PPT at the posterior superior iliac spine up to 30 minutes following the intervention.

Official Title
-----------------
Looking Beyond the Immediate Effects of Lumbar Spinal Manipulation Using Pain Pressure Threshold in Asymptomatic Individuals

Conditions
-----------------
Lumbar Spine Injury, Pain

Intervention / Treatment
-----------------
* Procedure: Sidelying lumbar manipulation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Asymptomatic individuals between the ages of 18-50 Exclusion Criteria: Current low back pain (LBP) A history of low back pain LBP within the last three months Previous spinal surgery Rheumatological condition or neurological symptoms or conditions Recent ingestion of pain-relieving medications within the last 24 hours A lumbar manipulation within three days prior to the exam Exhibited any contraindications to manipulation Positive findings during screening precautions

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Sidelying lumbar manipulation<br>Right sided lumbar manipulation | Procedure: Sidelying lumbar manipulation<br>* R sided lumbar manipulation<br>|
| Active Comparator: Sham ultrasound<br>Sham (non-therapeutic settings) ultrasound at the right PSIS | Procedure: Sidelying lumbar manipulation<br>* R sided lumbar manipulation<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain pressure threshold | PPT at the right PSIS | Baseline, Immediately after, 30 minutes after |
Atorvastatin as an Antihypertensive Agent

Study Overview
=================
Brief Summary
-----------------
This study is aimed to see the antihypertensive effect of statin (Atorvastatin) as certain animal models have shown that statins have the voltage-gated calcium channel blocking effect. It will be a randomized controlled trial that will be done in Ayub Hospital Complex Abbottabad. After ethical approval, 120 patients with newly diagnosed hypertension belonging to either gender and aged 35 and above will be enrolled in the trial. They will randomly be grouped into two groups with each group comprising 60 patients. One group will be administered Amlodipine 5 mg PO once a day, while the other one will be given 5mg Amlodipine plus 10 mg Atorvastatin. The patients will be examined on a follow-up visit 14 days later and blood pressure will be recorded as per protocols.

Official Title
-----------------
Effect of Atorvastatin in the Management of Hypertension

Conditions
-----------------
Atorvastatin Antihypertensive Effect

Intervention / Treatment
-----------------
* Drug: Amlodipine 5 MG Oral Tablet
* Drug: Amlodipine 5 MG / Atorvastatin 10 MG Oral Tablet


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - The inclusion criteria for the study were all newly diagnosed hypertensive patients aged 35 years and above with normal lipid profile Exclusion Criteria: Patients with a history of dyslipidemias, diabetes mellites, chronic kidney disease, and ischemic heart disease

Ages Eligible for Study
-----------------
Minimum Age: 35 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Amlopdipine only<br>Newly diagnosed hypertensive patients who will be given only amlodipine. | Drug: Amlodipine 5 MG Oral Tablet<br>* one group will be given only Amlodipine 5MG once daily<br>|
| Active Comparator: Amlodipine and Atorvastatin<br>Newly diagnosed hypertensive patients who will be given Amlodipine and Atorvastatin. | Drug: Amlodipine 5 MG / Atorvastatin 10 MG Oral Tablet<br>* one group will be given Amlodipine 5mg plus Atorvastatin 10MG once daily<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Antihypertensive effect of atorvastatin | patients receiving atorvastatin based combination should have more decrease in the blood pressure. | 14 days |
The Use of Reconstructive Surgery for Sexually Mutilated Women at the University Hospitals of Strasbourg

Study Overview
=================
Brief Summary
-----------------
Despite awareness since the 1980s and a legal framework to punish sexual mutilation, this tradition continues in many countries, particularly in Africa but not only in the Middle East, Malaysia and Indonesia. This custom, carried out among increasingly young little girls, exposes them to infectious, hemorrhagic and even death risks and sometimes significant obstetric complications. Every year, 3 million girls and young women are sexually mutilated around the world, or one woman every 15 seconds. In recent years, a surgical repair technique has been created by a French urologist, Professor Foldès. This technique allows clitoral reconstruction. Sensory reacquisition after this intervention may take a few months, but the functional results are quite good. There is little or no data concerning the use of reconstructive surgery for these mutilated patients consulting in sexology and the future of patients post-operatively or who have not had recourse to reconstructive surgery. The investigators then questioned the decision of these patients and their future.

Official Title
-----------------
Use of Reconstructive Surgery for Women Consulting in Sexology at the University Hospitals of Strasbourg for Sexual Mutilation

Conditions
-----------------
Sexual Trauma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult woman (≥18 years old) having consulted sexology at the HUS for sexual mutilation between 01/01/2011 and 12/31/2021. having had clitoral repair surgery at the HUS between 01/01/2011 and 12/31/2021 not objecting, after information, to the reuse of their data for the purposes of this research Exclusion Criteria: Woman who expressed her opposition to participating in the study impossibility of providing the subject with informed information (difficulties in understanding the subject, etc.) Woman under judicial protection or under guardianship or curatorship.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluation of the future of patients who consulted sexology for sexual mutilation between 2011 and 2021 at the HUS, whether or not they opted for reconstructive surgery. | This assessment is made via a questionnaire of nine questions relating to their future. | Through study completion, an average of 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Sexual mutilation
Empagliflozin in Heart Failure Dialysis Patients

Study Overview
=================
Brief Summary
-----------------
Empagliflozin is not still approved for glomerular filtration rate < 20 cc/min/1.73m2. Considering the cardiac and renal benefits of this drug, the evaluation of the safety and efficacy of Empagliflozin for heart failure dialysis patients seems to be mandatory.

Detailed Description
-----------------
Heart failure dialysis patients with residual renal function will be followed up on Empagliflozin based on echocardiographic parameters, pro-brain natriuretic peptide levels, diuresis volume, and serum acidity.

Official Title
-----------------
Safety and Efficacy of Empagliflozin on Heart Failure Dialysis Patients

Conditions
-----------------
Heart Failure, Hemodialysis

Intervention / Treatment
-----------------
* Drug: Empagliflozin10Mg Tab


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Heart failure on dialysis with residual renal function Exclusion Criteria: Dialysis patients with no residual urine
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Empagliflozin<br>Heart failure dialysis patients will be treated with Empagliflozin | Drug: Empagliflozin10Mg Tab<br>* 10 mg daily<br>* Other names: Abide;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Brain Natriuretic Peptide | serum level | one month after administration |
A Cohort of Patients With Phenotyped Diffuse Interstitial Lung Disease With Longitudinal Follow-up

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to conduct a descriptive analysis of the population of patients with an interstitial lung disease received in the pulmonary department of University hospital of Nice (France). Analysis and documentation of clinical forms of the disease, therapeutics used and evolutions.

Official Title
-----------------
A Cohort of Patients With Phenotyped Diffuse Interstitial Lung Disease With Longitudinal Follow-up

Conditions
-----------------
Interstitial Lung Disease

Intervention / Treatment
-----------------
* Other: Observation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age ≥ 18 years old Diagnosis of interstitial lung disease according to the multidisciplinary monthly meeting for interstitial lung disease occuring at University hospital of Nice, France Exclusion Criteria: Patient-led opposition to data collection

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Observation|Follow-up of disease, therapeutics and evolution|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Build a retrospective cohort of patients with phenotyped interstitial Lung disease with longitudinal follow-up |  | 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Follow-up of progression criteria according to diagnosis | Change in pulmonary functional tests | 2 years | 
| Follow-up of progression criteria according to diagnosis | Change in respiratory symptoms | 2 years | 
| Follow-up of progression criteria according to diagnosis | Change in High-resolution Computed Tomography (HRCT) images | 2 years | 
| Follow-up of progression criteria according to diagnosis | Impact of interstitial lung disease treatements | 2 years |
Evaluation of Efficacy and Safety of VX-548 for Painful Lumbosacral Radiculopathy (PLSR)

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to evaluate the efficacy and safety of VX-548 in treating participants with PLSR.

Official Title
-----------------
A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel-design Study of the Efficacy and Safety of VX-548 in Subjects With Painful Lumbosacral Radiculopathy

Conditions
-----------------
Painful Lumbosacral Radiculopathy

Intervention / Treatment
-----------------
* Drug: VX-548
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Key Inclusion Criteria: Body weight greater than or equal to (>=)45 kilogram (kg) Body mass index (BMI) less than or equal to (<=) 40 kg/ meter square (m^2) Diagnosis of PLSR for greater than (>)3 months as per criteria pre-specified in the protocol Weekly average of daily NPRS score >=4 and <10 with limited variation in the 7-day Run-in Period Key Exclusion Criteria: More than 3 missing daily NPRS scores during the 7-day Run-in Period Moderate or severe painful neuropathy other than PLSR as pre-specified in the protocol History of prior lumbar spine surgery (e.g., discectomies, laminectomies, foraminotomies, or fusion) Other protocol defined Inclusion/Exclusion criteria may apply.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: VX-548<br>Participants will receive VX-548 up to 12 weeks. | Drug: VX-548<br>* Tablets for oral administration.<br>|
| Placebo Comparator: Placebo<br>Participants will receive placebo matched to VX-548 up to 12 weeks. | Drug: Placebo<br>* Tablets for oral administration.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change From Baseline in the Weekly Average of Daily leg Pain Intensity on a Numeric Pain Rating Scale (NPRS) |  | Baseline, Week 12 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change From Baseline in the Weekly Average of the Daily Sleep Interference Scale (DSIS) |  | Baseline, Week 12 | 
| Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) |  | From Day 1 up to Week 14 |
Prevalence of Upper Limb Musculoskeletal Abnormalities in Type 2 Diabetic Patients and Its Relation to Hypoglycemic Control.

Study Overview
=================
Brief Summary
-----------------
to investigate prevalence of upper limb musculoskeletal disorders and correlations to glycemic control.

Detailed Description
-----------------
). DM is associated with a number of complications including renal disease, peripheral neuropathy, retinopathy, vascular events and musculoskeletal complications. DM is complicated by musculoskeletal problems of upper extremity and particularly the hand, collectively referred as the diabetic hand. (3) The most common upper limb musculoskeletal disorders associated with DM are adhesive capsulitis, rotator's cuff tendinitis, limited joint mobility (LJM), Dupuytren's disease (DD), trigger finger (TF), and carpal tunnel syndrome (CTS). Upper limb musculoskeletal disorders affect hand functions and activities of daily living (ADL). Aim of the study: to investigate prevalence of upper limb musculoskeletal disorders and correlations to glycemic control. Inclusion criteria: patients will be included to this study(cases) if they are: 1) Diabetic patients. 2) Age > 18 years. 3) Diagnosed as type 2. Exclusion criteria: Patients will be excluded if they have rheumatoid arthritis, other rheumatological diseases or previous upper limb surgeries. Sample size calculation: By reviewing literature, it is found that the most relevant study (3) to our work found that the prevalence of upper limb musculoskeletal abnormalities in type 2 diabetic patients is .22 and for control group is .05 so, by using piface calculator (version 1.76) to calculate sample size (power = 0.8, alpha error = 0.05 and beta= 0.2) it is found that we need 71 participants for every group. To increase power of the study will enroll 100 participants for every group.

Official Title
-----------------
Prevalence of Upper Limb Musculoskeletal Abnormalities in Type 2 Diabetic Patients and Its Relation to Glycemic Control.

Conditions
-----------------
Upper Limb Musculoskeletal Abnormalities

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients will be included to this study(cases) if they are: 1) Diabetic patients. 2) Age > 18 years. 3) Diagnosed as type 2. Exclusion Criteria: - Patients will be excluded if they have rheumatoid arthritis, other rheumatological diseases or previous upper limb surgeries.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Groupe(A)<br>Group (A)diabetics - g | |
| group(B)<br>group B normal is a normal control(non-diabetics) | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| prevalence of upper limb musculoskeletal disorders and correlations to glycemic control |  | 3 months |
AMO CROC Study: Self-medication and Dental Pain of Pulpal and Peri-apical Origin. Qualitative Study

Study Overview
=================
Brief Summary
-----------------
Adult patients with dental anxiety or phobia constitute a population for which access to dental care is difficult and this situation is often associated with am low socio-economic status. According to the literature, these patients avoid conventional care, make greater use of emergency services, and self-medicate when experiencing dental pain. Moreover, little is known in the literature about the use of self medication in France, although it is known that in the general population does self medicate a lot. The objective of this study is to better understand the self-medication behaviors of patients in order to improve their care. This work aim at characterizing a population of adults in need of treatment for dental pain of pulpal or periapical origin and anxious or phobic adults in need of for dental treatment under general anesthesia. Self-medication behaviors will be studied in qualitative research during recorded interviews.

Official Title
-----------------
AMO CROC Study: Self-medication and Dental Pain of Pulpal and Peri-apical Origin. Qualitative Study

Conditions
-----------------
Self Medication

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adults visiting the odontology unit for dental pain due to acute pulpitis or in need of dental treatment under general anesthesia Speaking French Able to give his/her informed consent Affiliated to the health social security system Exclusion Criteria: Adults under guardianship or curatorship Adults refusing to participate

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| self medication behaviors description | Describe and understand self medication behaviors in adults visiting the odontology unit for dental pain of acute pulpal origin and in need of dental treatment under general anesthesia, via a qualitative study. A semi-structured interview will be conducted. Participants will be interviewed alone. The interviews will be conducted in face-to-face in French, following this interview guide. The data will be analyzed continuously to stop the inclusion of patients when data's saturation is reached, when no new ideas are raised. Questions about self medication related to dentistry and anxiety of the dental environment will be asked. | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Dental anxiety, Qualitative, Behaviors, Self Medication
Evaluation of Vidiac Scores of Obese and Morbid Obese Patients Intubated by Videolaryngoscopy

Study Overview
=================
Brief Summary
-----------------
The aim of the study was to observe the vidiac score values of only patients with obesity as a risk factor for difficult intubation. Secondly, it was aimed to evaluate the number of intubation attempts and intubation time, vidiac scores between obese and morbid obese patients and to reveal the differences, if any.

Official Title
-----------------
Evaluation of Vidiac Scores of Obese and Morbid Obese Patients Intubated by Videolaryngoscopy

Conditions
-----------------
Vidiac Score, Videolaryngoscopy, Obesity, Morbid

Intervention / Treatment
-----------------
* Diagnostic Test: Vidiac Score


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All obese and morbidly obese patients to be operated under general anesthesia and endotracheal intubation Exclusion Criteria: under 18 years old The patient's refusal Difficult airway story before Congenital or previous airway anatomical disorder Patients who have undergone airway surgery Patients with a mass in the head and neck region Body mass ındex < 30 kg/m2

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| obese<br>Vidiac score Mallampati score upper lip bite test Thyromental distance Mandible ramus length Mouth opening distance | Diagnostic Test: Vidiac Score<br>* Vidiac score is a scoring system created according to the visibility of laryngeal structures under videolarnyngoscopy in patients with expected difficult intubation.<br>|
| Morbid obese<br>Vidiac score Mallampati score upper lip bite test Thyromental distance Mandible ramus length Mouth opening distance | Diagnostic Test: Vidiac Score<br>* Vidiac score is a scoring system created according to the visibility of laryngeal structures under videolarnyngoscopy in patients with expected difficult intubation.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| vidiac score | Vidiac score is a scoring system created according to the visibility of laryngeal structures under videoingoscopy in patients with expected difficult intubation. | during entubation |